This study examines the association between cost-sharing and initiation of disease-modifying therapies among privately insured patients with multiple sclerosis.
Homa Dastani, PhD
Advertisement
Articles by Homa Dastani, PhD
Advertisement
Latest Updated Articles
- Cost-Sharing and Initiation of Disease-Modifying Therapy for Multiple Sclerosis
Published: August 24th 2012 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
5
